Reasoning
The governing VCEP requires functional assay evidence meeting its specified acceptability criteria. The VCEP recognizes phosphorylation, DEPTOR binding, cell survivability, and cell proliferation assays as broadly accepted historically; a publication may support PS3 at the supporting level, while moderate evidence requires 8-34 variants and strong evidence requires 35 or more variants. Evidence above supporting additionally requires independent positive and negative validation controls, with WT and empty vector or blank transfection specified as basic controls and documented technical replicates of at least three for the relevant assay types. The available functional paper (PMID:29533785) does not report NM_006218.4:c.331_345del, p.(Lys111_Arg115del), or p.(K111_R115del); it reports a different single-residue PIK3CA K111delK variant. Therefore, no exact-variant functional result is available to assess PS3 at any strength.
VCEP rule
Brain Malformation Recommendation: Award PS3 if the functional assay meets the acceptability criteria delimited in (PMID: 31892348) with specifications added by the BMVCEP. Quality metrics and minimum validation controls required can be found in Supplementary Document 1.
Evidence considered
- ClinGen Brain Malformations VCEP specification v1.1, Supplementals, Document 1 (PS3), Functional Assay Validation: the four assay classes are phosphorylation, DEPTOR binding, cell survivability, and cell proliferation; any publication within the spreadsheet can support PS3 at supporting level; evidence above supporting requires positive and negative validation controls; 8-34 variants are required for moderate evidence and 35+ variants for strong evidence.
- ClinGen Brain Malformations VCEP specification v1.1, Supplemental Table 1: for phosphorylation/DEPTOR binding/cell survivability, WT is the basic positive control, empty vector or blank transfection may be the basic negative control, and technical replicates must be documented in at least triplicate; for cell proliferation, WT and empty vector or blank transfection are required as basic controls and technical replicates are required in triplicate or more.
- PMID:29533785 paper extraction: functional screening included 29 PIK3CA mutants in Ba/F3 cells, but the exact variant was not mentioned; PIK3CA K111delK, a different single-residue deletion, had the strongest activating mutation score in pooled and individual in-vitro formats.
Still missing
- The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf contains no entry for c.331_345del, p.Lys111_Arg115del, or p.K111_R115del.
- No publication in the available evidence reports a functional assay result for the exact five-residue deletion, so assay controls and variant-specific results cannot be evaluated.
Sources